Synaptogenix Launches $100M AI Token Treasury Strategy Focused On Bittensor (TAO) With $10M Initial Acquisition Led by Crypto Expert James Altucher

0.00% Pre

Synaptogenix Inc Ordinary Shares

SNPX

0.00

Singular focus on Bittensor (TAO), the leading AI token by

adoption and market capitalization

James Altucher to lead TAO token strategy initiatives

Planned initial acquisition of $10 million in TAO equates to over two times the Company's

current market capitalization; total acquisition target of $100 million

NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.

Synaptogenix plans to acquire $10 million in TAO tokens initially, which amounts to over two times the Company's current market valuation. The Company's strategy is targeted to acquire $100 million of TAO tokens. The initial acquisition will be funded by the Company's significant cash reserves and well-capitalized balance sheet.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

FOCUS-Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

Stock Volatility Alert | ASML(10.1%), TSM(6.8%) And GS(5.7%): Top Potential Volatility in Options to Watch This Week

'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment

How Investors Are Reacting To Nektar Therapeutics (NKTR) Securing FDA Fast Track For Eczema Drug Candidate

Assembly Biosciences Gains 13%, Insider Trades Reap Benefit

Johnson & Johnson Intends To Separate Its Orthopedics Business And Establish A Standalone Business Operating As DePuy Synthes

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Should Neurocrine Biosciences' (NBIX) KINECT-HD2 Data and New Leadership Prompt Investor Action?